Komipharm International Co Ltd

Komipharm has a market price of 7,520 KRW and a market capitalization of 540.75 billion KRW, with a price-to-book ratio of 7.78 and a price-to-tangible-book ratio of 7.78. The company's enterprise value to EBITDA ratio is 873.04, and its enterprise value to revenue ratio is 10.55. The company has a negative return on equity of -10.37% and a negative return on assets of -5.38%. The debt-to-equity ratio is 0.58, and the current ratio is 1.3. The company's profitability is significantly below industry norms, with a net loss of 7.21 billion KRW and negative operating income of 634 million KRW. The gross profit margin is 32.53%, but the company's overall financial performance is weak, as indicated by the negative return on equity and assets. Komipharm's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the financial snapshot. The company's revenue concentration in a single therapeutic area increases its exposure to market and regulatory risks. The company's revenue for the latest period is 52.47 billion KRW, but the outlook for the current fiscal year is uncertain due to the negative operating cash flow of 622 million KRW and free cash flow of -9.66 billion KRW. The capital expenditure of -4.47 billion KRW indicates significant investment in growth initiatives. The company faces liquidity risks due to a negative net cash position after subtracting total debt. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company has not disclosed any recent equity issuances or dilution events in the available data. No recent events or filings are disclosed in the available data to provide additional context on the company's operations or strategic direction.